LONDON (Reuters) - African babies -- the group most at risk of dying from malaria -- may be protected against the mosquito-borne disease by an experimental vaccine, researchers said on Wednesday.The finding clears the way for final-stage testing of GlaxoSmithKine Plc’s shot and increases the chance that the world will have a usable vaccine within five years.
